Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

January 15, 2020January 15, 2020

PH-HFpEF Patients Show Initial Response to Levosimendan in HELP Trial, Data Show

News, PH News

Preliminary data from the Phase 2 HELP study testing levosimendan as a potential treatment for pulmonary hypertension (PH) patients with heart failure and preserved ejection fraction (PH-HFpEF) showed that 86% of those analyzed responded to ... Read more

December 20, 2019December 20, 2019

INOpulse Improves Physical Activity of ILD Patients at Risk of PH, Phase 2/3 Results Show

News, PH News

Bellerophon Therapeutics’ vasodilator INOpulse increased physical activity and improved quality of life in people with interstitial lung disease (PH-ILD) who are at risk of pulmonary hypertension, top-line results from a ... Read more

December 11, 2019December 11, 2019

PH Linked to Worse Outcomes in Patients Undergoing Mitral Valve Repair, Study Reports

News, PH News

Pulmonary hypertension (PH) is highly prevalent and linked to increased mortality and hospitalization among patients who underwent minimally invasive transcatheter mitral valve repair — the repair of the valve ... Read more

November 27, 2019November 27, 2019

Liminal Biosciences’s PBI-4050 Reduces Pulmonary Hypertension, Preclinical Data Show

News, PH News

New preclinical data supports the positive effects of Liminal Biosciences’s lead candidate, PBI-4050, in reducing pulmonary hypertension and the abnormal enlargement of the heart’s right ventricle muscle. The company presented its ... Read more

November 6, 2019November 6, 2019

Prerequisite Response Achieved in 83% of Patients After Levosimendan Infusion in HELP Trial

News, PH News

Fifteen out of 18 patients (83%) enrolled in the Phase 2 HELP study testing levosimendan achieved the predefined response required in the open-label phase of the study, Tenax Therapeutics announced. The investigational therapy ... Read more

October 25, 2019October 25, 2019

Rodatristat Ethyl May Reduce Serotonin Production and Affect Vascular Remodeling in PAH Patients, Study Suggests

News, PAH News

Oral treatment with rodatristat ethyl is safe and reduced the levels of serotonin — a hormone whose high levels may promote the tightening of pulmonary artery muscle cells — ... Read more

October 23, 2019October 23, 2019

Opsumit-Adcirca Combo Improves Blood Flow and Physical Capacity in People New to PAH, Trial Data Show

News

A combination of Opsumit (macitentan) plus Adcirca (tadalafil) lowered pulmonary vascular resistance — a measure showing how well blood flows through vessels — by 47% in people newly diagnosed with pulmonary arterial ... Read more

October 9, 2019October 9, 2019

Low Blood Levels of Secretin Hormone May Trigger PH, Mouse Study Suggests

News, PH News

Loss of a hormone called secretin (SCT) induces hypertension, scarring, and structural alterations in the heart and lungs, a study in mice reports. The study “Loss of secretin results ... Read more

October 4, 2019October 4, 2019

Halting Slug Protein May Lessen Risk of PH in Fibrotic Lungs, Study Suggests

News

Halting a protein called Slug may help reduce the severity of increased blood pressure related to lung scarring — a condition called pulmonary hypertension (PH) secondary to pulmonary fibrosis, ... Read more

August 1, 2019August 2, 2019

Adempas May Improve Endothelial Cells’ Function in CTEPH, Study Suggests

CTEPH News, News

The vasodilator Adempas (riociguat) increases the ability of endothelial progenitor cells to halt vascular remodeling and enhance formation of new blood vessels in chronic thromboembolic pulmonary hypertension (CTEPH), according to a new ... Read more

Pin It on Pinterest